Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours

Histopathology

Volumn 50, Issue 5, 2007, Pages 597-606

  La Rosa, S ^a,b   Rigoli, E ^a   Uccella, S ^a   Novario, R ^a   Capella, C ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Cytokeratin 19; Endocrine tumours; Pancreas; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BA17; MONOCLONAL ANTIBODY RCK108; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD VESSEL; CANCER INVASION; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOREACTIVITY; INSULINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PANCREAS TUMOR; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ISLET CELL; CELL PROLIFERATION; CHILD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INSULINOMA; ISLETS OF LANGERHANS; KERATIN-19; KI-67 ANTIGEN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33947614079     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02662.x     Document Type: Article

References (26)

1. Solcia E, Kloppel G, Sobin LH et al. Histological typing of endocrine tumours, 2nd edn. Berlin: Springer-Verlag 2000.
2. DeLellis RA, Lloyd RV, Heitz PU et al. WHO classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press 2004.
3. Chang HJ, Batts KP, Lloyd RV et al. Prognostic significance of p27, Ki-67, and topoisomerase IIα expression in clinically nonfunctioning pancreatic endocrine tumors. Endocr. Pathol. 2000; 11; 229-241.
4. Chaudhry A, Öberg K, Wilander E. A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumor Biol. 1992; 13; 27-35.
5. Clarke MR, Baker EV, Weyant RJ et al. Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocr. Pathol. 1997; 8; 181-187.
6. DeLellis RA. Does the evaluation of proliferative activity predict malignancy or prognosis in endocrine tumors? Hum. Pathol. 1995; 26; 131-133.
7. Gentil-Perret AG, Mosnier JF, Buono JP et al. The relationship between MIB-1 proliferation index and outcome in pancreatic neuroendocrine tumors. Am. J. Clin. Pathol. 1998; 109; 286-293.
8. Kimura N, Miura W, Noshiro T et al. Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr. Pathol. 1994; 5; 223-228.
9. La Rosa S, Sessa F, Capella C et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch. 1996; 429; 323-333.
10. Lloyd RV. Proliferative markers in the study of endocrine diseases. Endocr. Pathol. 1995; 6; 83-86.
11. Lloyd RV. Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. Am. J. Clin. Pathol. 1998; 109; 245-247.
12. Pelosi G, Zamboni G, Doglioni C et al. Immunodetection of proliferating cell nuclear antigen assesses the growth fraction and predicts malignancy in endocrine tumors of the pancreas. Am. J. Surg. Pathol. 1992; 16; 1215-1225.
13. Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy. A comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum. Pathol. 1996; 27; 1124-1134.
14. Pelosi G, Zamboni G. Proliferation markers and their uses in the study of endocrine tumors. Endocr. Pathol. 1996; 7; 103-119.
15. Pelosi G, Pasini F, Bresaola E et al. High-affinity monomeric 67-kD laminin receptors and prognosis in pancreatic endocrine tumors. J. Pathol. 1997; 183; 62-69.
16. Deshpande V, Fernandez-del Castillo C, Muzikansky A et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am. J. Surg. Pathol. 2004; 28; 1145-1153.
17. Bouwens L. Cytokeratins and cell differentiation in the pancreas. J. Pathol. 1998; 184; 234-239.
18. Real FX, Vila MR, Skoudy A et al. Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer. Int. J. Cancer 1993; 54; 720-727.
19. Bouwens L, Lu WG, De Krijger R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia 1997; 40; 398-404.
20. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique. J. Histochem. Cytochem. 1981; 25; 577-589.
21. Bartek J, Durban EM, Hallowes RC et al. A subclass of luminal epithelial cells in the human mammary gland, defined by antibodies to cytokeratins. J. Cell. Sci. 1985; 75; 17-33.
22. Kwaspen FHL, Smedts FMM, Broos A et al. Reproducibile and highly sensitive detection of the broad spectrum epithelial marker keratin 19 in routine cancer diagnosis. Histopathology 1997; 31; 503-516.
23. Barbareschi M, Murer B, Colby TV et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am. J. Surg. Pathol. 2003; 27; 141-149.
24. La Rosa S, Rigoli E, Uccella S et al. CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors. Virchows Arch. 2004; 445; 248-254.
25. Kapran Y, Ozturk AS, Gulluoglu MG et al. Does expression of cytokeratin 19 in pancreatic endocrine tumors correlate with the WHO classification? Virchows Arch. 2005; 447; 188.
26. Solcia E, Klöppel G, Capella C. Tumors of the exocrine pancreas. In Rosai J, Sobin LH eds. Tumors of the pancreas. Atlas of tumor Pathology, 3rd edn. Washington DC: Armed Forces Institute of Pathology 1997; 31-144.